Moderna reported fourth-quarter earnings that exceeded Wall Street expectations, but the stock still declined in after-hours trading. The biotechnology company delivered strong financial results, driven by robust sales of its COVID-19 vaccine and other products. Revenue and earnings per share both surpassed analyst forecasts, demonstrating the company's continued commercial strength despite a challenging market environment.

However, the positive financial news was overshadowed by a regulatory setback. The FDA raised concerns about Moderna's experimental mRNA-based flu vaccine, which the company had hoped would become a major growth driver. The regulatory agency requested additional data before approving the vaccine for emergency use authorization, potentially delaying its market launch by several months.

The dual nature of the announcement - strong earnings but regulatory headwinds - created a mixed reaction from investors. While the quarterly results showed Moderna's core business remains healthy, the FDA setback raises questions about the company's pipeline and future growth prospects. This highlights the delicate balance between near-term financial performance and long-term pipeline development that biotech stocks must navigate.